Before Bulletin No. 13, Health Canada expected product licence holders to align labels affected by monograph revisions with the latest version of the monograph within three years of publication, at the next label run, or with the next post-licensing change (amendment or notification), whichever came first. Natural Health Product Licensing Bulletin No. 13 provides administrative flexibility to defer monograph-related label updates until the end of the new transition period for forthcoming NHP labelling amendments. Health Canada has not yet set that end date.
The announcement follows Health Canada’s commitment to make NHP labelling requirements more flexible under its broader Red Tape Reduction initiative. Health Canada plans to pre-publish draft amendments to the Natural Health Products Regulations in the Canada Gazette, Part I, in spring 2027. The draft amendments are expected to include a proposed transition period extending beyond June 2028; its length has not yet been determined. The interim flexibility does not apply to safety-related labelling changes separately directed by Health Canada, which must be implemented within the timelines specified in the applicable notice, request, or direction.
For NHP manufacturers and licence holders, the announcement provides an opportunity to reassess planned labelling updates, distinguish between deferred monograph revisions and mandatory safety requirements, and coordinate future packaging changes with the anticipated regulatory amendments.
In June 2022, Health Canada introduced amendments to the Natural Health Products Regulations intended to improve the clarity, consistency, and legibility of information presented on NHP labels. The amendments established new requirements for standardized Product Facts Tables, improved font sizes and contrast, priority allergen declarations, and modernized contact information, with the objective of helping consumers make informed decisions about the products they use.
To support implementation, Health Canada also committed to reviewing its Compendium of Monographs, which establishes standardized conditions of use for commonly used NHP ingredients and product categories. These monographs provide an important regulatory reference for product licensing, including recommended uses, doses, routes of administration, risk information, and other conditions that may affect approved product labelling.
The monograph review was originally expected to be completed by 2025, allowing manufacturers to incorporate updated monograph information alongside the broader labelling amendments and minimize the need for multiple packaging revisions. However, the review process extended into 2026, creating additional challenges for licence holders preparing to meet the regulatory transition deadlines.
Throughout this period, Health Canada conducted a series of consultations on proposed monograph revisions, including the Batch 4a and Batch 4b consultations released in 2024. These consultations addressed a range of medicinal ingredients and product categories, with proposed changes affecting conditions of use, ingredient concentrations, and other information relevant to product licensing and labelling.
At the same time, industry stakeholders raised concerns about the cost and complexity of implementing the new labelling requirements, particularly for products with limited packaging space or extensive mandatory information. In response, Health Canada introduced additional transitional flexibility, including a March 2025 exemption order for newly licensed NHPs and a subsequent extension of the broader labelling compliance timeline announced in Natural Health Product Licensing Bulletin No. 10.
The October 2026 bulletin represents the latest development in this process, aligning implementation of monograph-related label changes with Health Canada’s plans to reconsider aspects of the underlying labelling requirements.
Bulletin No. 13 is an interim administrative approach. It allows product licence holders to defer monograph-related label updates until the end of the new transition period for forthcoming labelling amendments, but it does not set a date for that transition period or finalize the proposed regulatory amendments. The distinction is significant because monograph revisions and the broader NHP labelling amendments are related but separate regulatory initiatives. Monographs establish accepted conditions of use for NHP ingredients and products, while the 2022 labelling amendments introduced additional requirements governing how information must be presented to consumers.
By coordinating implementation of these initiatives, Health Canada intends to provide licence holders with greater flexibility to manage their labelling obligations without requiring repeated changes to packaging and printed materials.
The following table summarizes how Health Canada’s compliance approach has evolved and what the October 2026 announcement means for NHP licence holders.
| Regulatory Area | Previous Approach | October 2026 Interim Approach |
| Monograph-related label updates | Licence holders were expected to align affected labels with the latest monograph within three years of publication, at the next label run, or with the next post-licensing change (amendment or notification), whichever came first. | Bulletin No. 13 provides administrative flexibility to defer these label updates until the end of the new transition period for forthcoming labelling amendments. The end date has not yet been set. |
| Broader NHP labelling requirements | The current transition period for the 2022 labelling amendments ends in June 2028. | Health Canada plans to propose a new transition period extending beyond June 2028. The proposed timeline and amendments have not been finalized. |
| Regulatory framework | The 2022 amendments established new requirements for label content and presentation. | Further amendments are being developed to introduce additional flexibility. |
| Safety-related label changes | Safety-related labelling changes directed by Health Canada must be implemented within the timelines specified in its notice, request, or direction. | This requirement remains unchanged. Bulletin No. 13’s flexibility does not apply to these directed changes. |
| Next regulatory milestone | Implementation planning was based on the existing regulatory framework and transition dates. | Draft amendments are expected in spring 2027, including consultation on a revised transition timeline. |
Bulletin No. 13 addresses monograph-related label updates only. It does not establish the end date of the new transition period or finalize the proposed regulatory amendments. Licence holders should distinguish label updates covered by this interim approach from safety-related changes separately directed by Health Canada, which remain subject to their specified timelines.
Bulletin No. 13’s interim flexibility does not apply when Health Canada separately directs a labelling change to address a safety concern. If Health Canada issues a regulatory notice, request, or other direction requiring a safety-related label change, product licence holders must follow the timeline specified in that communication.
Because monographs can contain both conditions of use and safety information, licence holders should assess the nature of each change. A label update arising from the general monograph revision initiative may be deferred under Bulletin No. 13. A safety-related change separately directed by Health Canada must still be implemented within the specified timeline.
Health Canada has also encouraged licence holders to voluntarily adopt applicable monograph updates where feasible. Companies that are already revising labels, updating packaging, or preparing new product launches may therefore choose to incorporate relevant changes in advance, provided their labels remain consistent with applicable regulatory requirements and product authorizations.
The October 2026 announcement is part of Health Canada’s broader commitment to reduce unnecessary regulatory burden while maintaining appropriate health and safety protections. In September 2025, Health Canada and the Public Health Agency of Canada published their Report on Red Tape Reduction, identifying initiatives intended to simplify regulatory processes, improve flexibility, and support more efficient compliance across regulated industries.
For the NHP sector, one of the Department’s commitments involves revisiting labelling requirements introduced under the 2022 amendments. Industry concerns regarding prescriptive formatting, packaging limitations, implementation costs, and the complexity of compliance have contributed to the decision to pursue a more flexible regulatory approach.
The Department has indicated that proposed amendments to the Natural Health Products Regulations are targeted for pre-publication in the Canada Gazette, Part I, in spring 2027. These amendments are expected to include a proposed transition period extending beyond June 2028, with stakeholders having an opportunity to provide feedback before the regulatory framework is finalized.
At this stage, Health Canada has not confirmed the length of the new transition period or the specific labelling provisions that may be revised. The forthcoming consultation will therefore be an important opportunity for manufacturers, licence holders, and industry associations to evaluate the proposed changes and communicate any remaining implementation challenges.
Licence holders should identify products affected by monograph revisions and determine which label updates fall within Bulletin No. 13’s interim flexibility. They should separately track safety-related changes directed by Health Canada, which remain subject to the timelines in the applicable communication.
Companies may voluntarily adopt applicable monograph updates where feasible. They should also monitor the proposed amendments expected in spring 2027 and review the proposed transition timeline once it is published for consultation.
Bulletin No. 13 changes the timing expectation for monograph-related label updates, allowing them to be deferred until the end of a new transition period that Health Canada has not yet set. Separately directed safety-related label changes remain subject to their specified timelines. Licence holders should apply this distinction when planning label updates while Health Canada develops the proposed amendments.
Navigating changes to Health Canada’s NHP labelling requirements requires a clear understanding of both existing regulatory obligations and the flexibility introduced through recent policy announcements. Determining which monograph updates can be deferred, which safety-related changes remain mandatory, and how proposed amendments may affect product portfolios is an important part of effective regulatory planning.
With more than 20 years of experience supporting the Natural Health Products industry, dicentra’s regulatory affairs team helps manufacturers and product licence holders navigate evolving Health Canada requirements. As Health Canada prepares further changes to its NHP labelling framework, our specialists can help companies evaluate their obligations and develop practical strategies for maintaining compliance while minimizing unnecessary revisions.
Our Natural Health Product regulatory services include:
Contact dicentra today to discuss how Health Canada’s interim compliance approach may affect your NHP products and labelling strategy.